More dilution is on the way before a licensing deal is made.
Good post. We will see about this last statement. From the 10Q they are still working on licensing PCa test with an interested party and also (HIV region specific). They raised $4.4M last week and $3M a couple weeks before that. The vote is 6 weeks away, over which time we should learn a lot more information and that $4.4M cash matches exactly with one month burn rate in Q1, which could drop more in Q2 (as low as $3.5M per month), down from $5.5M per month burn in Q4 as noted in the 10Q because of less needed for CMO now. It is possible that $4.4M last week was the end of paulson, because they could get the deal done over the next 6 weeks, but they definitively need to show and have a backup if the deal does not go through. Even then I would not expect the big $30M cash raises of the past needed for the BLA, probably more like the last two months until the get more cancer data, complete bla filing, mono pivotal trial, etc, to ignite the share price first. JMO.
I haven’t forgotten about and NP has been very nicely awarded for that. I’m not getting paid today because I’ve done such a wonderful job in the past. It’s not about what you’ve done, but what you’re doing today and frankly spoken NP is a mediocre CEO at best. We’ve got a proven product and yet the share prize doesn’t reflect that, doesn’t recognize this. Whose task is it to create shareholder value? Exactly. Doing a poor job, can’t make any more of it.
Market Data 
Markets 
AI
